Authors
Nicolino Ruperto, Kevin J Murray, Valeria Gerloni, Nico Wulffraat, Sheila Knupp Feitosa De Oliveira, Fernanda Falcini, Pavla Dolezalova, Maria Alessio, Ruben Burgos‐Vargas, Fabrizia Corona, Richard Vesely, Helen Foster, Joyce Davidson, Francesco Zulian, Line Asplin, Eileen Baildam, Julia Garcia Consuegra, Huri Ozdogan, Rotraud Saurenmann, Rik Joos, Angela Pistorio, Pat Woo, Alberto Martini
Publication date
2004/7
Journal
Arthritis & Rheumatism: Official Journal of the American College of Rheumatology
Volume
50
Issue
7
Pages
2191-2201
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Description
Objective
To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m2/week) versus a higher dosage (30 mg/m2/week) in patients with polyarticular‐course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8–12.5 mg/m2/week).
Methods
In the screening phase, 595 patients who were newly started on a standard dose of MTX were followed up for 6 months. Subsequently, the nonresponders, defined according to the American College of Rheumatology (ACR) pediatric 30% improvement criteria (pediatric 30), were randomized to receive an intermediate dose or higher dose of parenteral MTX for an additional 6 months. Improvement in the screening and randomization phase was defined by the ACR pediatric 30 response, as well as by the 50% and 70% response levels (ACR pediatric 50 and ACR pediatric 70 …
Total citations
Scholar articles
N Ruperto, KJ Murray, V Gerloni, N Wulffraat… - Arthritis & Rheumatism: Official Journal of the American …, 2004